Achillion Pharmaceuticals’ (ACHN) Neutral Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their neutral rating on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in a research report released on Sunday.

Other analysts have also recently issued reports about the company. BidaskClub upgraded Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, August 16th. Robert W. Baird restated a neutral rating and set a $4.00 price objective (down from $5.00) on shares of Achillion Pharmaceuticals in a research report on Tuesday, September 12th. ValuEngine cut Achillion Pharmaceuticals from a sell rating to a strong sell rating in a research report on Monday, September 11th. Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $6.50.

Achillion Pharmaceuticals (NASDAQ ACHN) opened at 4.09 on Friday. The firm’s market cap is $559.35 million. The firm has a 50-day moving average of $4.48 and a 200-day moving average of $4.20. Achillion Pharmaceuticals has a 12-month low of $3.15 and a 12-month high of $9.19.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). During the same period last year, the business earned ($0.14) EPS. On average, analysts expect that Achillion Pharmaceuticals will post ($0.66) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Achillion Pharmaceuticals’ (ACHN) Neutral Rating Reiterated at Chardan Capital” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/21/achillion-pharmaceuticals-achn-neutral-rating-reiterated-at-chardan-capital.html.

A number of large investors have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. grew its position in Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 800 shares during the period. Canada Pension Plan Investment Board grew its position in Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 1,600 shares during the period. Schwab Charles Investment Management Inc. grew its position in Achillion Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock valued at $2,100,000 after acquiring an additional 2,850 shares during the period. Bank of Montreal Can grew its position in Achillion Pharmaceuticals by 6.4% in the second quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 3,410 shares during the period. Finally, Wells Fargo & Company MN grew its position in Achillion Pharmaceuticals by 1.8% in the second quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 3,827 shares during the period. Hedge funds and other institutional investors own 74.11% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply